This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24
ASX:LGP
MCAP $25.64M
This browser does not support the video element.